Review of Notable Adverse Events Associated with Acellular Pertussis Vaccination: A Narrative Overview
-
By
-
Lennart Nilsson
-
Jann Storsaeter
-
July 12, 2026
Clinical Scorecard: Review of Notable Adverse Events Associated with Acellular Pertussis Vaccination: A Narrative Overview
At a Glance
| Category | Detail |
|---|
| Condition | Acellular Pertussis Vaccination |
| Key Mechanisms | Adverse events following immunization (AEFI) including local and systemic reactions. |
| Target Population | Infants receiving DTaP and Tdap vaccines. |
| Care Setting | Immunization programs in pediatric healthcare settings. |
Key Highlights
- Acellular pertussis vaccines have lower rates of adverse events compared to whole-cell vaccines.
- Mild adverse events include local reactions and low-grade fever.
- Moderate adverse events include extensive limb swelling and hypotonic hyporesponsive episodes.
- Serious adverse events include anaphylaxis and acute disseminated encephalomyelitis (ADEM).
- Surveillance for AEFIs has been implemented globally since the introduction of acellular vaccines.
Guideline-Based Recommendations
Diagnosis
- Monitor for mild, moderate, and serious AEFIs post-vaccination.
Management
- Provide supportive care for mild and moderate AEFIs.
- Investigate serious AEFIs such as anaphylaxis and ADEM.
Monitoring & Follow-up
- Systematic surveillance for AEFIs should be maintained.
Risks
- Infants under 6 months are at higher risk for hypotonic hyporesponsive episodes.
Patient & Prescribing Data
Infants receiving DTaP and Tdap vaccines.
Vaccination is associated with a range of mild to serious adverse events, necessitating careful monitoring.
Clinical Best Practices
- Educate caregivers about potential AEFIs.
- Ensure proper reporting and documentation of AEFIs.
- Follow up with patients experiencing moderate to serious AEFIs.
Related Resources & Content
